Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bites and Stings Clear all
Active, not recruiting Phase 1 Interventional

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional

Volume vs Concentration: Quadratus Lumborum Blocks With High Volume/Low Concentration or Low Volume/ High Concentration in Nephrectomies

NCT04077398
View directory record Official record
Conditions
Analgesia, Postoperative Pain, Block
Interventions
Ropivacaine 0.5% Injectable Solution
Drug
Lead sponsor
Bruce Ben-David
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2Phase 3 Interventional

Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

NCT00685230
View directory record Official record
Conditions
Scorpion Sting Envenomation
Interventions
Antivenin Centruroides (scorpion) equine immune F(ab)2, Placebo
Biological · Other
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 2, 2026, 1:35 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT07280013
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
Cemsidomide, Elranatamab
Drug · Biological
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 2, 2026, 1:35 AM EDT
Completed No phase listed Observational

Clinical and Immunological Evaluation of Children With Allergies

NCT00102570
View directory record Official record
Conditions
Hypersensitivity, Immediate
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Maintaining Patency in Implanted Port Catheters

NCT02354118
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
8
States / cities
Cincinnati, Ohio • Hamilton, Ohio • Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery

NCT01986751
View directory record Official record
Conditions
Pain
Interventions
Clonidine, ropivacaine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Black Widow Spider Antivenin for Patients With Systemic Latrodectism

NCT00657540
View directory record Official record
Conditions
Latrodectism
Interventions
Analatro, Saline
Drug
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery

NCT01118117
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Misago™ Self-Expanding Stent System
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
View directory record Official record
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Recruiting Not applicable Interventional

ESP Block in MIS Lumbar Spine Surgery

NCT05856539
View directory record Official record
Conditions
Patients With Spinal Stenosis Indicated for MIS TLIF
Interventions
Erector spinae plane (ESP) block
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism

NCT00247078
View directory record Official record
Conditions
Arachnidism, Latrodectism
Interventions
widow spider antivenom, Placebo
Biological
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Dose Response of a Tubule Occlusion Agent

NCT01075256
View directory record Official record
Conditions
Dentine Hypersensitivity, Dental Pain
Interventions
5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste, Placebo toothpaste
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

NCT00624078
View directory record Official record
Conditions
Scorpion Sting Envenomation
Interventions
Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Drug
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
Not listed
Enrollment
1,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Casa Grande, Arizona • Chandler, Arizona • Douglas, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 2, 2026, 1:35 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

NCT01724580
View directory record Official record
Conditions
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Not listed Not applicable Interventional

Decision Aid for Parents of Infants With UPJO

NCT05900375
View directory record Official record
Conditions
Ureteropelvic Junction Obstruction, Ureteropelvic Junction; Obstruction, Congenital
Interventions
Parent Decision Aid
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 2, 2026, 1:35 AM EDT
Approved For Marketing No phase listed Expanded access

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

NCT06064500
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Active, not recruiting Not applicable Interventional Results available

ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

NCT03499964
View directory record Official record
Conditions
Urethral Stricture
Interventions
Optilume Drug Coated Balloon (DCB), Control Treatment
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 2, 2026, 1:35 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects

NCT05507164
View directory record Official record
Conditions
Occlusion
Interventions
Temporomasseteric Nerve Block
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 1 Interventional

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

NCT04609579
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Lymphoma
Interventions
SNX281, pembrolizumab
Drug
Lead sponsor
Stingthera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention of Jellyfish Stings

NCT00114894
View directory record Official record
Conditions
Bites and Stings
Interventions
Safe Sea ™, Placebo
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Key West, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 1:35 AM EDT